Caladrius Biosciences (NASDAQ:CLBS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Monday.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, HC Wainwright initiated coverage on shares of Caladrius Biosciences in a research note on Tuesday, November 20th. They issued a “buy” rating and a $18.50 price objective for the company.
NASDAQ CLBS traded up $0.02 during trading on Monday, reaching $5.25. The company’s stock had a trading volume of 17,100 shares, compared to its average volume of 22,086. The stock has a market capitalization of $51.47 million, a PE ratio of -2.95 and a beta of 1.89. Caladrius Biosciences has a 1-year low of $3.05 and a 1-year high of $11.65.
Caladrius Biosciences (NASDAQ:CLBS) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.20. On average, analysts expect that Caladrius Biosciences will post -1.75 EPS for the current fiscal year.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc lifted its position in Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,568 shares of the biotechnology company’s stock after buying an additional 5,700 shares during the quarter. Vanguard Group Inc owned about 2.06% of Caladrius Biosciences worth $1,196,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.73% of the company’s stock.
About Caladrius Biosciences
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.